clinical trial · NCT07518771
PA-001 Ph.1 Study in Healthy and Elderly Subjects
PeptiDream Inc.·phase1·completed·n = 47
COVID - 19PA-001
brief summary
This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts. The principal aim of this study was to obtain safety and tolerability data when PA-001 is administered IV as single and multiple doses to healthy subjects. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The study also investigated the effects of age on the PK of PA-001 prior to patient studies.
started
Jul 30, 2024
primary completion
Jun 2, 2025
completion
Jun 2, 2025
last updated
Apr 9, 2026
official title
PA-001 - A Phase 1, Double Blind, Randomized, Placebo Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics in Healthy and Elderly Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol